Anti-androgen for treating metastatic castration-sensitive prostate cancer

The present invention provides an anti-androgen for treating metastatic castration-sensitive prostate cancer, which includes, but is not limited to 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.


File format
PDF
Published
16 November, 2023
Updated
16 November, 2023
MD5 checksum
3BC98B26E330752223FD4E7A968CF9F2
Download PDF

Also Manuals